Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

AQW-051

From Wikipedia, the free encyclopedia
(Redirected fromAQW051)
Nicotinic agonist medication

Pharmaceutical compound
AQW-051
Clinical data
Other namesAQW051, VQW-765
Identifiers
  • (3R)-3-{[6-(4-methylphenyl)pyridin-3-yl]oxy}-1-azabicyclo[2.2.2]octane
CAS Number
PubChemCID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC19H22N2O
Molar mass294.398 g·mol−1
3D model (JSmol)
  • CC1=CC=C(C=C1)C2=NC=C(C=C2)O[C@H]3CN4CCC3CC4
  • InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m0/s1
  • Key:NPDLTEZXGWRMLQ-IBGZPJMESA-N

AQW-051 also known asVQW-765 is an orally available, highly selectivepartial agonist of thealpha-7 nicotinic receptor (nAChR)[1][2] developed byNovartis as acentral nervous system agent aimed at improvingcognitive function in disorders such asschizophrenia andAlzheimer's disease, and for reducingL-Dopa–induceddyskinesias inParkinson's disease.[1] AQW-051 had reached Phase 2 clinical trials for conditions like schizophrenia and Parkinson’s disease, but development for Alzheimer’s disease has been discontinued.[3][4]

It was later licensed it toVanda Pharmaceuticals and who are evaluating it in phase 3 clinical trials forphobic disorders[5] andsocial anxiety.[6]

References

[edit]
  1. ^abDi Paolo T, Grégoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B (November 2014). "AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys".Parkinsonism & Related Disorders.20 (11):1119–1123.doi:10.1016/j.parkreldis.2014.05.007.PMID 25172125.
  2. ^Feuerbach D, Pezous N, Weiss M, Shakeri-Nejad K, Lingenhoehl K, Hoyer D, et al. (March 2015)."AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation".British Journal of Pharmacology.172 (5):1292–304.doi:10.1111/bph.13001.PMC 4337702.PMID 25363835.
  3. ^Barch DM, Marder SR, Harms MP, Jarskog LF, Buchanan RW, Cronenwett W, et al. (November 2016)."Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial".Progress in Neuro-psychopharmacology & Biological Psychiatry.71:66–75.doi:10.1016/j.pnpbp.2016.06.013.PMC 6432789.PMID 27371157.
  4. ^Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, et al. (July 2016). "A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia".Movement Disorders.31 (7):1049–54.doi:10.1002/mds.26569.PMID 26990766.
  5. ^"VQW-765".AdisInsight. Springer Nature Switzerland AG.
  6. ^He Y, Polymeropoulos CM, Mohrman MA, Truslow SO, Xiao C, Wu Y, et al. (July 2025)."Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial".The British Journal of Psychiatry.227 (1):473–480.doi:10.1192/bjp.2025.84.PMC 12278049.PMID 40340771.
Psychoanaleptics: Anti-dementia agents (ATC codeN06D and others)
AChE inhibitor medications
Other medications
ExperimentalBACE inhibitors
nAChRsTooltip Nicotinic acetylcholine receptors
Agonists
(andPAMsTooltip positive allosteric modulators)
Antagonists
(andNAMsTooltip negative allosteric modulators)
Precursors
(andprodrugs)
Stub icon

Thispharmacology-related article is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=AQW-051&oldid=1336661277"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp